Ospemifene for vulvar and vaginal atrophy

Phase 3, randomised, double-blind trial of ospemifene in vulvovaginal atrophy (VVA) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Mean Change From Baseline in the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom (MBS) of Vaginal Dryness at 12 weeks, Mean Change From Baseline in the MBS of Vaginal Pain Associated With Sexual Activity at 12 weeks and 3 more. Started Jan 2006; status: completed.